When childhood atopic dermatitis persists into adulthood, the large reduction in quality of life suggests that the price of ...

The company has previously reported positive data for its PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...